Key Points
- Director Charles Kummeth purchased 500,000 shares of Quantum‑Si at an average price of $0.92 per share (≈$460,000), bringing his direct ownership to 855,000 shares — a 140.85% increase — as disclosed in an SEC filing.
- QSI trades near $0.93 with a market cap of about $199.5M; the company reported a ($0.08) EPS that beat estimates but posted weak revenue, and analysts hold a consensus "Hold" rating with a $3.25 target amid recent price‑target cuts.
Quantum-Si Incorporated (NASDAQ:QSI - Get Free Report) Director Paula Dowdy purchased 109,890 shares of the business's stock in a transaction dated Thursday, March 5th. The stock was bought at an average price of $0.95 per share, for a total transaction of $104,395.50. Following the completion of the acquisition, the director directly owned 269,107 shares in the company, valued at approximately $255,651.65. This trade represents a 69.02% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Quantum-Si Price Performance
Shares of NASDAQ QSI opened at $0.93 on Tuesday. The stock has a market capitalization of $199.52 million, a P/E ratio of -1.78 and a beta of 3.00. Quantum-Si Incorporated has a 1-year low of $0.84 and a 1-year high of $3.10. The business has a fifty day moving average price of $1.09 and a 200 day moving average price of $1.37.
Quantum-Si (NASDAQ:QSI - Get Free Report) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.06. Quantum-Si had a negative return on equity of 43.90% and a negative net margin of 4,160.06%.The company had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.76 million. As a group, equities research analysts anticipate that Quantum-Si Incorporated will post -0.65 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group cut their price objective on shares of Quantum-Si from $1.50 to $1.00 and set a "hold" rating on the stock in a research report on Wednesday, March 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Quantum-Si in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $3.25.
Get Our Latest Stock Analysis on Quantum-Si
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in Quantum-Si in the fourth quarter valued at about $262,000. Invesco Ltd. grew its stake in shares of Quantum-Si by 36.2% during the fourth quarter. Invesco Ltd. now owns 402,821 shares of the company's stock worth $443,000 after acquiring an additional 107,093 shares during the last quarter. XTX Topco Ltd increased its holdings in shares of Quantum-Si by 206.9% during the fourth quarter. XTX Topco Ltd now owns 461,982 shares of the company's stock valued at $508,000 after acquiring an additional 311,450 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of Quantum-Si during the fourth quarter valued at about $305,000. Finally, Barclays PLC raised its position in shares of Quantum-Si by 21.8% in the 4th quarter. Barclays PLC now owns 269,415 shares of the company's stock valued at $296,000 after purchasing an additional 48,205 shares during the last quarter. 39.90% of the stock is owned by institutional investors and hedge funds.
About Quantum-Si
(
Get Free Report)
Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.
Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
